Treatment endpoints for advanced cholangiocarcinoma
Gregory J Gores*, Edwina S Baskin-Bey, Todd H Baron and Steven R Alberts
Correspondence *Mayo Clinic College of Medicine, 200 First Street SW, Rochester MN 55905 USA
Email gores.gregory@mayo.edu
At present, there is no standard treatment for cholangiocarcinoma, a fatal cancer of the biliary tree. New therapies for cholangiocarcinoma are difficult to evaluate because treatment endpoints are ill-defined. This viewpoint explains why the current endpoints are problematic and proposes a new quantitative system for assessing disease progression.
Full text of this article is available with one of the following:
- Membership of the American College of Gastroenterology. If already a member, please login.
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
